Please login to the form below

Not currently logged in
Email:
Password:

heart attack

This page shows the latest heart attack news and features for those working in and with pharma, biotech and healthcare.

Amgen gets prevention claim for cholesterol drug Repatha

Amgen gets prevention claim for cholesterol drug Repatha

Amgen gets prevention claim for cholesterol drug Repatha. FDA approves new labelling on heart attack and stroke risk reduction. ... The new label is based on the results of the FOURIER trial, which showed that the drug reduced the risk of heart attack by

Latest news

  • Alcon's return to growth gives Novartis 'options', says CEO Alcon's return to growth gives Novartis 'options', says CEO

    Immunotherapy Cosentyx (secukinumab) for psoriasis, ankylosing spondylitis and psoriatic arthritis rocketed 90% to reach $490m in the quarter, while slow-burner Entresto (sacubitril and valsartan) for heart failure contributed $110m and ... A string of

  • CV data sets up Novartis' Ilaris for blockbuster sales CV data sets up Novartis' Ilaris for blockbuster sales

    with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... Novartis' chief medical officer Vas Narasimhan is hopeful. "Despite current treatment, about 25% of heart attack survivors will have another cardiovascular

  • Repatha outcomes data Repatha outcomes data "less than stellar"

    After a follow-up period of around two years, it showed that the risk of heart attack, stroke and coronary revascularisation was cut by 27%, 21% and 22%, respectively. ... Repatha was also able to reduce an extended array of MACE endpoints – including

  • New outcomes data could unlock Repatha's potential, says Amgen New outcomes data could unlock Repatha's potential, says Amgen

    In the four-year FOURIER trial - which involved 27, 500 patients - the drug significantly reduced the risk of heart attack, stroke and death in patients with heart disease in patients with

  • Novartis boosts cardiovascular pipeline with $1bn Ionis deal Novartis boosts cardiovascular pipeline with $1bn Ionis deal

    The agreement covers drugs designed to reduce two well-characterised factors - lipoprotein(a) and apolipoprotein CIII - that elevate the risk of serious complications such as heart attack and stroke in patients ... The company launched first-in-class

More from news
Approximately 5 fully matching, plus 211 partially matching documents found.

Latest Intelligence

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”.

  • Why health psychology is the answer to tackling adherence Why health psychology is the answer to tackling adherence

    Therapy (OAP), a treatment that has been shown to reduce the risk of death or non-fatal heart attack.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. “ ... After a heart attack people tend to leave the hospital thinking the event is over.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    Cardiovascular diseases – such as heart attack, stroke, DVT and atrial fibrillation – also present a major problem in Russia, with 46 per cent of self-reported sufferers (39 per cent being diagnosed). ... Analysts predict that ischaemic heart disease

  • Healthcare industry apps Healthcare industry apps

    machine to detect abnormal heart rhythms or determine if a patient is experiencing a heart attack).' At time of writing, these guidelines have yet to be finalised, although plenty of companies ... Edwards Heart Master. Developed by Edwards Life Sciences,

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics